Xcelience Receives CEO Cancer Gold StandardTM Accreditation

TAMPA, Fla.--(BUSINESS WIRE)-- Xcelience, LLC has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, nearly one million and a quarter employees and family members are benefiting from the vision and leadership of employers who have chosen to become Gold Standard accredited.

"Thanks to the leadership and commitment to employee health of President and CEO Derek G. Hennecke, Xcelience is now a Gold Standard bearer,” said Weldon. “We hope this commitment will continue in helping to ensure that employees from numerous other employers will be covered under this standard of excellence in cancer prevention, early detection, and quality care.”

The CEO Cancer Gold Standard™ calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.

Other organizations joining Xcelience in championing this workplace-based effort to eliminate cancer as a public health threat include: Aetna, Aldagen, Inc., the American Cancer Society’s National Home Office and Mid-South Division, the American Legacy Foundation, the American Society of Clinical Oncology, Aptuit, AstraZeneca, C-Change, Cigna, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, Fox Chase Cancer Center, GlaxoSmithKline, Hogan & Hartson, Independence Blue Cross, Jenner & Block, Johnson & Johnson, the Lance Armstrong Foundation, LiDestri Foods, M. D. Anderson Cancer Center, MDU Resources, Meridian Health, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute, Nevada Cancer Institute, Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Pride, Inc., Quest Diagnostics, Quintiles Transnational, sanofi-aventis, SAS Institute, St. Barnabas Health Care System, State Farm, Susan G. Komen for the Cure, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health, WCA Hospital and the Wistar Institute.

About Xcelience

Xcelience LLC, is a contract research organization providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company prides itself on a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab.

About Xcelience: Keep on top of new developments in Xcelience and throughout the drug development industry by following us on Twitter www.twitter.com/Xcelience. For more detailed information, visit www.xcelience.com .

About The CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. For more information on the CEO Cancer Gold Standard™ and the web-based accreditation process and support, please visit www.CancerGoldStandard.org.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6259898&lang=en



CONTACT:

Xcelience, LLC
Kim Black-Washington, Director, Marketing & Strategic Development, 206-525-5852
[email protected]
or
CEO Roundtable on Cancer
John Dornan, Executive Director, 919-531-0966
[email protected]

KEYWORDS:   United States  North America  Florida

INDUSTRY KEYWORDS:   Women  Other Consumer  Health  Biotechnology  Clinical Trials  Fitness & Nutrition  Oncology  Pharmaceutical  Radiology  Other Health  Research  Other Science  FDA  Consumer  Family  Science  General Health  Men

MEDIA:

Logo
 Logo

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.